Medical practice guidelines.

Por Rajkumar, S V, Sampathkumar, P
Publicado em 1994

Waldenstrom macroglobulinemia: prognosis and management

Por Oza, A, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Waldenstrom macroglobulinemia: prognosis and management

Por Oza, A, Rajkumar, S V
Publicado no Blood Cancer J (2016)

Conflict of interest in academic oncology: moving beyond the blame game and forging a path forward

Por Prasad, V, Rajkumar, S V
Publicado no Blood Cancer J (2016)

Interpretation of cytogenetic results in multiple myeloma for clinical practice

Por Rajan, A M, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial

Por Gertz, Morie A., Abonour, Rafat, Heffner, Leonard T., Greipp, Philip R., Uno, Hajime, Rajkumar, S. V.
Publicado em 2009

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

Por Vu, T, Gonsalves, W, Kumar, S, Dispenzieri, A, Lacy, M Q, Buadi, F, Gertz, M A, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

Por Chanan-Khan, A A, Swaika, A, Paulus, A, Kumar, S K, Mikhael, J R, Rajkumar, S V, Dispenzieri, A, Lacy, M Q
Publicado em 2013

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study

Por Greenberg, A J, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, R A, Kumar, S, Vachon, C M, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have co...

Por Jacobus, S J, Rajkumar, S V, Weiss, M, Stewart, A K, Stadtmauer, E A, Callander, N S, Dreosti, L M, Lacy, M Q, Fonseca, R
Publicado no Blood Cancer J (2016)

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study

Por Greenberg, A J, Philip, S, Paner, A, Velinova, S, Badros, A, Catchatourian, R, Ketterling, R, Kyle, R A, Kumar, S, Vachon, C M, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy

Por Siontis, B, Kumar, S, Dispenzieri, A, Drake, M T, Lacy, M Q, Buadi, F, Dingli, D, Kapoor, P, Gonsalves, W, Gertz, M A, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 random...

Por Biran, N, Jacobus, S, Vesole, D H, Callander, N S, Fonseca, R, Williams, M E, Abonour, R, Katz, M S, Rajkumar, S V, Greipp, P R, Siegel, D S
Publicado no Blood Cancer J (2016)

Impact of high-risk classification by FISH: An Eastern Cooperative Oncology Group (ECOG) study E4A03

Por Jacobus, S. J., Kumar, S., Uno, H., Van Wier, S. A., Ahmann, G. J., Henderson, K. J., Callander, N. S., Williams, M. E., Siegel, D. S., Greipp, P. R., Rajkumar, S. V., Fonseca, R.
Publicado em 2011

Prevalence, incidence and survival of smoldering multiple myeloma in the United States

Por Ravindran, A, Bartley, A C, Holton, S J, Gonsalves, W I, Kapoor, P, Siddiqui, M A, Hashmi, S K, Marshall, A L, Ashrani, A A, Dispenzieri, A, Kyle, R A, Rajkumar, S V, Go, R S
Publicado no Blood Cancer J (2016)

RELATIONSHIP BETWEEN ELEVATED IMMUNOGLOBULIN FREE LIGHT CHAIN AND THE PRESENCE OF IgH TRANSLOCATIONS IN MULTIPLE MYELOMA

Por Kumar, S., Zhang, L., Dispenzieri, A., Van Wier, S., Katzmann, J.A., Snyder, M., Blood, E., DeGoey, R., Henderson, K., Kyle, R.A., Bradwell, A.R., Greipp, P.R., Rajkumar, S.V., Fonseca, R
Publicado em 2010

Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10–49 years old: a population-based study from the National Health and...

Por Landgren, O, Graubard, B I, Kumar, S, Kyle, R A, Katzmann, J A, Murata, K, Costello, R, Dispenzieri, A, Caporaso, N, Mailankody, S, Korde, N, Hultcrantz, M, Therneau, T M, Larson, D R, Cerhan, J R, Rajkumar, S V
Publicado no Blood Cancer J (2017)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

Por Roy, V, Stewart, A K, Bergsagel, P L, Dispenzieri, A, Laumann, K, Allred, J, Lacy, M Q, Fonseca, R, Reeder, C B, Kumar, S, Rivera, C E, Gertz, M A, Buadi, F K, Hayman, S R, Rajkumar, S V
Publicado no Blood Cancer J (2015)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

Por Ravi, P, Kumar, S, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R S, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado no Blood Cancer J (2017)

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

Por Gonsalves, W I, Leung, N, Rajkumar, S V, Dispenzieri, A, Lacy, M Q, Hayman, S R, Buadi, F K, Dingli, D, Kapoor, P, Go, R S, Lin, Y, Russell, S J, Lust, J A, Zeldenrust, S, Kyle, R A, Gertz, M A, Kumar, S K
Publicado no Blood Cancer J (2015)